. 2006 Sep 19;6:8. doi: 10.1186/1471-5945-6-8
Copyright © 2006 Papp and Henninger; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1.
Patients achieving SPC on efalizumab at week 12.